MX2020007552A - Composicion farmaceutica estable que comprende esomeprazol y bicarbonato de sodio. - Google Patents
Composicion farmaceutica estable que comprende esomeprazol y bicarbonato de sodio.Info
- Publication number
- MX2020007552A MX2020007552A MX2020007552A MX2020007552A MX2020007552A MX 2020007552 A MX2020007552 A MX 2020007552A MX 2020007552 A MX2020007552 A MX 2020007552A MX 2020007552 A MX2020007552 A MX 2020007552A MX 2020007552 A MX2020007552 A MX 2020007552A
- Authority
- MX
- Mexico
- Prior art keywords
- sodium bicarbonate
- pharmaceutical composition
- stable pharmaceutical
- esomeprazole
- relates
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención se relaciona con una composición farmacéutica estable que comprende omeprazol, su enantiómero o su sal farmacéuticamente aceptable, y bicarbonato de sodio. Específicamente, la presente invención se relaciona con una composición farmacéutica con estabilidad mejorada que comprende una dosis baja de bicarbonato de sodio, de modo que tiene una tasa de disolución y disponibilidad mejoradas y también reduce los efectos secundarios que resultan de una alta dosis de bicarbonato de sodio.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020180010980A KR102080023B1 (ko) | 2018-01-29 | 2018-01-29 | 에스오메프라졸 및 탄산수소나트륨을 포함하는 안정한 약제학적 조성물 |
PCT/KR2019/000309 WO2019146937A1 (en) | 2018-01-29 | 2019-01-09 | Stable pharmaceutical composition comprising esomeprazole and sodium bicarbonate |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020007552A true MX2020007552A (es) | 2020-09-09 |
Family
ID=67395505
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020007552A MX2020007552A (es) | 2018-01-29 | 2019-01-09 | Composicion farmaceutica estable que comprende esomeprazol y bicarbonato de sodio. |
Country Status (7)
Country | Link |
---|---|
US (1) | US11813285B2 (es) |
JP (1) | JP7003279B2 (es) |
KR (1) | KR102080023B1 (es) |
CN (1) | CN111727036B (es) |
BR (1) | BR112020014306A2 (es) |
MX (1) | MX2020007552A (es) |
WO (1) | WO2019146937A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102006777B1 (ko) | 2018-01-29 | 2019-10-08 | 주식회사 종근당 | 에스오메프라졸 및 탄산수소나트륨을 포함하는 약제학적 제제 |
KR102080023B1 (ko) | 2018-01-29 | 2020-02-21 | 주식회사 종근당 | 에스오메프라졸 및 탄산수소나트륨을 포함하는 안정한 약제학적 조성물 |
US20220288045A1 (en) * | 2019-07-26 | 2022-09-15 | Chong Kun Dang Pharmaceutical Corp. | Stable Pharmaceutical Composition Comprising Esomeprazole And Sodium Bicarbonate |
KR102494141B1 (ko) * | 2019-10-18 | 2023-02-01 | 주식회사 대웅테라퓨틱스 | 프로톤 펌프 저해제 및 탄산수소나트륨을 포함하는 안정한 약제학적 조성물 및 이의 제조방법 |
KR20220028789A (ko) | 2020-08-31 | 2022-03-08 | 진양제약주식회사 | 에스오메프라졸 함유 다층 정제 |
KR20230035991A (ko) * | 2021-09-06 | 2023-03-14 | 한국유나이티드제약 주식회사 | 라베프라졸과 탄산수소나트륨을 포함하는 약학조성물 |
KR20240030479A (ko) | 2022-08-31 | 2024-03-07 | 한올바이오파마주식회사 | 에스오메프라졸 및 제산제를 포함하는 약제학적 제제 및 이의 제조방법 |
Family Cites Families (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2189698A (en) * | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated omeprazole tablets |
KR100274698B1 (ko) | 1992-09-29 | 2000-12-15 | 손정삼 | 다층 알칼리 코팅에 의한 오메프라졸의 경구제제 및 그 제조방법 |
CN1138534C (zh) | 1994-07-08 | 2004-02-18 | 阿斯特拉曾尼卡有限公司 | 多单元片剂 |
KR960003605A (ko) | 1994-07-19 | 1996-02-23 | 김충식 | 해조류(海藻類)성분이 함유된 저염(低鹽) 재제염의 제조방법 |
US6489346B1 (en) * | 1996-01-04 | 2002-12-03 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
US6645988B2 (en) * | 1996-01-04 | 2003-11-11 | Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
US6699885B2 (en) * | 1996-01-04 | 2004-03-02 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and methods of using same |
SE9600071D0 (sv) | 1996-01-08 | 1996-01-08 | Astra Ab | New oral formulation of two active ingredients I |
SE510650C2 (sv) | 1997-05-30 | 1999-06-14 | Astra Ab | Ny förening |
JP2003073270A (ja) | 2001-08-30 | 2003-03-12 | Nisshin Seiyaku Kk | 安定性および溶出性の良好なプラバスタチンナトリウム錠 |
SE0203065D0 (sv) | 2002-10-16 | 2002-10-16 | Diabact Ab | Gastric acid secretion inhibiting composition |
US20050220870A1 (en) | 2003-02-20 | 2005-10-06 | Bonnie Hepburn | Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid |
ES2338009T3 (es) | 2003-07-11 | 2010-05-03 | Astrazeneca Ab | Composicion solida que comprende un inhibidor de la bomba de protones. |
AR045068A1 (es) | 2003-07-23 | 2005-10-12 | Univ Missouri | Formulacion de liberacion inmediata de composiciones farmaceuticas |
KR100581967B1 (ko) | 2003-12-18 | 2006-05-22 | 한국유나이티드제약 주식회사 | 소화성 궤양 치료를 위한 프로톤펌프 저해제와클래리스로마이신을 함유하는 이중 펠렛 제제 및 그의제조방법 |
US20050214371A1 (en) | 2004-03-03 | 2005-09-29 | Simona Di Capua | Stable pharmaceutical composition comprising an acid labile drug |
JP2007532677A (ja) | 2004-04-16 | 2007-11-15 | サンタラス インコーポレイティッド | プロトンポンプ阻害剤、緩衝剤、および運動促進薬の組み合わせ |
US8906940B2 (en) | 2004-05-25 | 2014-12-09 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
MXPA06013585A (es) | 2004-05-25 | 2009-07-22 | Santarus Inc | Formulaciones farmaceuticas utiles para inhibir la secrecion de acido y metodos para hacer y utilizar las mismas. |
US8815916B2 (en) | 2004-05-25 | 2014-08-26 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
WO2007049098A2 (en) | 2004-06-18 | 2007-05-03 | Neurochem (International) Limited | Therapeutic formulations for the treatment of beta-amyloid related diseases |
US20100029654A1 (en) * | 2006-03-23 | 2010-02-04 | Mount Sinai School Of Medicine | Cardiovascular compositions and use of the same for the treatment of alzheimer's disease |
CH698658B1 (de) * | 2006-04-24 | 2009-09-30 | Mepha Ag | Orale pharmazeutische Formulierung mit schneller Freisetzung für Pyridylmethylsulfinyl-Benzimidazole. |
US20090092658A1 (en) * | 2007-10-05 | 2009-04-09 | Santarus, Inc. | Novel formulations of proton pump inhibitors and methods of using these formulations |
EP2068841B1 (en) | 2006-10-05 | 2018-09-26 | Santarus, Inc. | Novel formulations of proton pump inhibitors and methods of using these formulations |
CN101002769A (zh) * | 2007-01-12 | 2007-07-25 | 广东华南药业有限公司 | 奥美拉唑组合物制剂 |
CN101259108A (zh) | 2007-03-09 | 2008-09-10 | 上海艾力斯医药科技有限公司 | 包含酸不稳定药物的双单元片剂 |
CN100490790C (zh) | 2007-04-28 | 2009-05-27 | 杭州民生药业集团有限公司 | 一种奥美拉唑肠溶微丸胶囊及其制备方法 |
AU2008304033B2 (en) | 2007-09-28 | 2014-05-01 | Ctc Bio, Inc. | Pharmaceutical composition containing esomeprazole |
EP2252274A4 (en) | 2008-02-20 | 2011-05-11 | Univ Missouri | COMPOSITION COMPRISING A COMBINATION OF OMEPRAZOLE AND LANSOPRAZOLE, AND A BUFFER AGENT, AND METHODS OF USING THE SAME |
CA2733299A1 (en) | 2008-08-11 | 2010-02-18 | Mepha Gmbh | Oral pharmaceutical formulation for omeprazole comprising a specific separation layer |
KR20110079641A (ko) | 2008-09-09 | 2011-07-07 | 아스트라제네카 아베 | 제약 조성물을 이를 필요로 하는 환자에게 전달하는 방법 |
KR20100066742A (ko) | 2008-12-10 | 2010-06-18 | 삼일제약주식회사 | 안정화된 프로톤 펌프 억제제 함유 약학 조성물 |
JP2012518655A (ja) | 2009-02-23 | 2012-08-16 | アプタリス ファーマテック インコーポレイテッド | プロトンポンプ阻害剤を含む制御放出組成物 |
KR101270751B1 (ko) | 2010-05-06 | 2013-06-07 | (주)비씨월드제약 | 위 체류 및 방출 조절을 위한 조성물 |
CN102078616A (zh) * | 2011-01-28 | 2011-06-01 | 北京虹湾医药技术有限公司 | 埃索美拉唑碳酸氢钠组合物 |
CN102397277A (zh) | 2011-11-17 | 2012-04-04 | 成都欣捷高新技术开发有限公司 | 包含埃索美拉唑的药物组合物 |
KR101907690B1 (ko) | 2012-04-12 | 2018-10-15 | 한미약품 주식회사 | 비스테로이드성 항염증약물 및 프로톤 펌프 저해제를 포함하는 약제학적 복합제제 및 이의 제조방법 |
CN103006691B (zh) | 2013-01-05 | 2014-10-08 | 青岛大学 | 一种含奥美拉唑碳酸氢钠复方胶囊制剂 |
US9901650B2 (en) | 2013-02-21 | 2018-02-27 | University Of Rochester | Methods for evaluating brain-wide paravascular pathway for waste clearance function and methods for treating neurodegenerative disorders based thereon |
CN103599082A (zh) | 2013-04-05 | 2014-02-26 | 黑龙江福和华星制药集团股份有限公司 | 奥美拉唑和碳酸氢钠包芯片 |
CN103784414B (zh) | 2013-12-18 | 2018-01-30 | 北京华禧联合科技发展有限公司 | 一种埃索美拉唑肠溶片及其制备方法 |
KR102242670B1 (ko) | 2014-01-09 | 2021-04-20 | 일동제약(주) | 둘록세틴이 함유된 안정한 다중코팅 정제 조성물 |
CN103860584B (zh) | 2014-02-25 | 2015-09-30 | 厦门恩成制药有限公司 | 一种奥美拉唑碳酸氢钠胶囊的制作方法 |
CN103845734A (zh) | 2014-03-20 | 2014-06-11 | 辽宁亿灵科创生物医药科技有限公司 | 埃索美拉唑药物组合物及其制剂 |
KR101723266B1 (ko) | 2014-08-13 | 2017-04-05 | 영남대학교 산학협력단 | 비스테로이드성 항염증약물 및 프로톤 펌프 저해제를 포함하는 경구용 속방형 조성물 및 그 제조방법 |
EP3236952B1 (en) | 2014-12-23 | 2019-07-03 | KRKA, d.d., Novo mesto | Pharmaceutical tablet composition |
CN204428461U (zh) | 2014-12-29 | 2015-07-01 | 黑龙江福和华星制药集团股份有限公司 | 埃索美拉唑碳酸氢钠片中片 |
KR102289011B1 (ko) | 2014-12-31 | 2021-08-11 | 한미약품 주식회사 | 비스테로이드성 항염증제 및 프로톤 펌프 저해제를 포함하는 경구용 서방성 복합제제 |
CN104523746B (zh) | 2015-02-02 | 2017-07-07 | 长春海悦药业股份有限公司 | 一种埃索美拉唑镁碳酸氢钠组合物 |
AU2016218992C1 (en) | 2015-02-10 | 2019-09-26 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
KR20160124368A (ko) | 2015-04-17 | 2016-10-27 | 대원제약주식회사 | 프로피온산 계열의 비스테로이드성 항염증 약물(nsaid) 및 프로톤 펌프 저해제(ppi)를 함유하는 생체이용률이 증진된 약제학적 조성물 |
KR102408645B1 (ko) | 2015-12-24 | 2022-06-14 | (주)휴온스 | 안정성이 증가된 에스오메프라졸 함유 이중코팅정 조성물 및 이의 제조방법 |
EP3402338B1 (en) | 2016-01-16 | 2023-06-07 | D.Y. Seligman Consulting Ltd. | Low carbohydrate sugar fondant |
KR101841662B1 (ko) * | 2016-06-02 | 2018-03-23 | 동화약품주식회사 | 프로톤 펌프 저해제의 고체분산체 및 이를 포함하는 약제학적 조성물 |
JP6859043B2 (ja) | 2016-07-22 | 2021-04-14 | キヤノン株式会社 | 液体吐出ヘッド |
KR101907116B1 (ko) | 2016-07-25 | 2018-10-11 | 한미약품 주식회사 | 에스오메프라졸, 또는 약학적으로 허용 가능한 그의 염을 포함하는, pH-의존성 약물 방출 특성이 개선된 제형 |
KR101911021B1 (ko) | 2017-02-27 | 2018-10-25 | 한국과학기술원 | 필름기반 통합칩 및 이의 핵산 검출 방법 |
KR102227486B1 (ko) | 2017-06-30 | 2021-03-12 | 롯데정밀화학 주식회사 | 프로톤 펌프 저해제를 포함하는 경구용 고형제제 조성물, 이를 포함하는 경구용 고형제제 및 그 제조방법 |
JP2020535113A (ja) | 2017-09-28 | 2020-12-03 | ハンミ ファーマシューティカルズ カンパニー リミテッド | エソメプラゾール、及びその薬学的に許容可能な塩を含むマルチユニット球状錠剤を含む薬剤学的組成物、並びにその製造方法 |
KR102080023B1 (ko) | 2018-01-29 | 2020-02-21 | 주식회사 종근당 | 에스오메프라졸 및 탄산수소나트륨을 포함하는 안정한 약제학적 조성물 |
KR102006777B1 (ko) | 2018-01-29 | 2019-10-08 | 주식회사 종근당 | 에스오메프라졸 및 탄산수소나트륨을 포함하는 약제학적 제제 |
BR112021002796A2 (pt) | 2018-08-23 | 2021-05-04 | Chong Kun Dang Pharmaceutical Corp. | composição farmacêutica e método para preparar uma composição farmacêutica |
-
2018
- 2018-01-29 KR KR1020180010980A patent/KR102080023B1/ko active IP Right Grant
-
2019
- 2019-01-09 MX MX2020007552A patent/MX2020007552A/es unknown
- 2019-01-09 US US16/965,748 patent/US11813285B2/en active Active
- 2019-01-09 CN CN201980009694.6A patent/CN111727036B/zh active Active
- 2019-01-09 JP JP2020541432A patent/JP7003279B2/ja active Active
- 2019-01-09 WO PCT/KR2019/000309 patent/WO2019146937A1/en active Application Filing
- 2019-01-09 BR BR112020014306-5A patent/BR112020014306A2/pt active Search and Examination
Also Published As
Publication number | Publication date |
---|---|
JP2021512081A (ja) | 2021-05-13 |
KR102080023B1 (ko) | 2020-02-21 |
CN111727036B (zh) | 2023-04-11 |
KR20190091879A (ko) | 2019-08-07 |
BR112020014306A2 (pt) | 2020-12-08 |
CN111727036A (zh) | 2020-09-29 |
JP7003279B2 (ja) | 2022-01-20 |
US20210030786A1 (en) | 2021-02-04 |
US11813285B2 (en) | 2023-11-14 |
WO2019146937A1 (en) | 2019-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020007552A (es) | Composicion farmaceutica estable que comprende esomeprazol y bicarbonato de sodio. | |
MX2021014509A (es) | Composiciones farmaceuticas que comprenden meloxicam. | |
PH12016501310A1 (en) | Pharmaceutical compositions comprising azd9291 | |
MX2020007554A (es) | Formulacion farmaceutica que comprende esomeprazol y bicarbonato de sodio. | |
PH12017502431A1 (en) | Pharmaceutical formulations comprising tenofovir and emtrictabine | |
MY187047A (en) | Selective pyy compounds and uses thereof | |
EA201691454A1 (ru) | Композиции придопидина модифицированного высвобождения | |
EA201792591A1 (ru) | Фармацевтические препараты | |
MX2021001905A (es) | Preparacion farmaceutica que tiene excelentes propiedades de disolucion, que contiene esomeprazol y bicarbonato de sodio. | |
MA39765A (fr) | Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation | |
PH12019500154A1 (en) | Formulation having improved ph-dependent drug-release characteristics, containing esomeprazole or pharmaceutically acceptable salt thereof | |
PH12017501829A1 (en) | Pharmaceutical formulations | |
MX2019008338A (es) | Composicion farmaceutica que contiene sulglicotido o una sal farmaceuticamente aceptable del mismo para la prevencion o tratamiento del ojo seco. | |
MX2022000968A (es) | Composicion farmaceutica estable que comprende esomeprazol y bicarbonato de sodio. | |
MY188302A (en) | Solid pharmaceutical composition comprising amlodipine and losartan | |
MX2017008983A (es) | Composición farmaceútica de sulfonamida. | |
EA201991286A1 (ru) | Твердая фармацевтическая композиция для перорального применения, содержащая тенофовир и эмтрицитабин | |
MX2021011795A (es) | Composición farmaceutica que comprende esomeprazol 0 sal farmaceuticamente aceptable del mismo y que tiene un perfil de liberación doble. | |
PH12016502527A1 (en) | Stabilized desmopressin | |
EA201991007A1 (ru) | Твердые фармацевтические композиции на основе гидрохлорида луразидона для перорального применения | |
EA201691763A1 (ru) | Стабильная быстрорастворимая лекарственная форма, содержащая амоксициллин и клавулановую кислоту | |
PH12018500946A1 (en) | Pharmaceutical composition containing, as active ingredient, 7-azaindolin-2-one derivative or pharmaceutically acceptable salt thereof | |
JOP20170198A1 (ar) | صيغ صيدلية تشتمل على تينوفوفير و إيمترايسيتابين | |
PH12020550597A1 (en) | Formulation having improved hygroscopic property and dissolution rate comprising telmisartan or its pharmaceutically acceptable salt | |
WO2019151966A3 (en) | Pharmaceutical tablet compositions of dabigatran |